



**DALLAS COUNTY
COUNTY AUDITOR**

Memorandum

To: Zachary Thompson
Director Health & Human Services

From: Virginia Porter *Virginia Porter*
County Auditor

Subject: International Travel
Inventory Report

DATE: Issued: October 18, 2012
Released: November 2, 2012

On August 31, 2012, our Internal Audit staff performed the annual physical vaccine inventory of International Travel.

Our specific procedures, findings, recommendations and departmental responses are listed in the attached report. Procedural changes regarding inventory control are needed. The report is intended for information and the use of management. We believe that enhanced record keeping procedures will allow for more effective operation and control of the inventory.

We appreciate the level of courtesy and cooperation extended during our review.

Attachments

cc: VP: tb

**DALLAS COUNTY, TEXAS-COUNTY AUDITORS OFFICE
HHS-INTERNATIONAL TRAVEL DEPARTMENT VACCINE INVENTORY
10/18/2012**

Scope

As a part of ongoing review of Health & Human Services (HHS) financial controls, the processes relevant to HHS-International Travel (IT) vaccine inventory were tested as of August 31, 2012. The purpose of this review was limited to the reconciliation of departmental records to physical count and the official general ledger. Other procedures for testing internal control and any findings are reported separately.

Background

Principal areas of responsibility for HHS-IT are to provide Dallas County citizens lower cost alternatives to vaccinations required by schools and other governmental agencies. The department is a part of the Preventative Health unit and consists of one nursing supervisor, four clerks, a cashier, and two nurses. The International Travel office is located in the Dallas County Health and Human Services building located at 2377 North Stemmons Freeway, Dallas, Texas.

Procedures

This report details the flow of vaccines into and out of the department, and lists the physical balances, by vaccine, at month end. There was no perpetual inventory in place at the time of this review.

Procedures included but were not limited to:

- generating listing of inventory items
- physically counting stock
- listing items issued during the taking of the inventory
- reviewing current pricing for vaccines purchased
- calculating "book" inventories based on monthly reports to Texas Department of State Health Services
- review and testing a sample of purchases and issues of vaccines
- comparison of purchases to the general ledger

Findings

1. Inventory as follows:

	<u>Unit</u>	<u>Inventory</u>	<u>Average</u>
August 31, 2012	13,178	\$441,523.39	\$33.50
August 31, 2011	<u>11,217</u>	<u>\$340,420.91</u>	<u>\$30.35</u>
Net Change	1,961	\$101,102.48	\$3.15

	Sept '10 thru Aug '11	Sept '11 thru Aug '12	Increase / Decrease	Percentage Change
Patients Seen	5,633	7,539	1,906	33.836%
Adjusted Vaccine Purchases (excludes supplies)	\$ 646,082.06	\$ 951,850.10	\$ 305,768.04	47.33%
Revenue	\$816,465.94	\$ 1,093,441.41	\$ 276,975.47	33.924%

DALLAS COUNTY, TEXAS-COUNTY AUDITORS OFFICE
HHS-INTERNATIONAL TRAVEL DEPARTMENT VACCINE INVENTORY
10/18/2012

Prices per dose are reviewed annually by the Assistant Director of Finance, Budget and Contracts and adjusted appropriately based on costs. Multiple vaccine suppliers are used to purchase vaccines. Inventory tracking is accomplished by the use of TWICES and Adult Biological Reports. Product cost is recorded to the General Ledger expenditure accounts with year-end reclass to inventory based on physical counts. Book inventory is derived from the Monthly Adult Biological Reports (Actual Physical Count Prior Month + Dose Received Current Month - Usable Doses Returned Current Month - Doses Administered Current Month - Expired Doses Returned Current Month - Doses Transferred Out Current Month) as reported by HHS.

The "Net" variance between the ending physical count, and the calculated "Book" inventory was (17) (0.128%) units under the vaccines on hand as of August 31, 2012. Conversion of the variance to a monetary amount based on ending inventory prices results in a \$751.19 decrease in "Book" inventory.

HHS completes a self-inventory each month and compares to the calculated inventory. Comparison of monthly data from October 2011 through August 2012 revealed the calculated inventory balance was 23 units under the actual physical inventory count on August 31, 2012. A summary of variances (physical count over (under) calculated count) exceeding \$100 as confirmed by Internal Audit for the month of August 2012 only vaccine inventory is listed below:

Meningococcal (Menactra) was under by 7 doses totaling \$(524.37)
Typhoid (Inject) was over by 3 doses totaling \$149.06
PCV-13 was over by 1 does totaling \$ 128.76
HPV-Gardasil was under by 1 doses totaling \$(150.36)
HPV (PED) was over by 1 does totaling \$ 136.19

Recommendations

The physical inventory value of \$441,523.39 as of August 31, 2012 should be updated to reflect actual value as of September 30, 2012 for reporting on the CAFR.

1. Establish a perpetual inventory system and determine variances between physical and book inventories monthly with variances documented throughout the year and inventory balances adjusted accordingly. Lot numbers should be properly recorded and referenced on all inventory transactions.

Response: HHS will continue to keep track of vaccine inventory through daily logs, monthly stock-taking process and the monthly reporting process. Variances in inventory between book balance and actual count will be explained and documented as is done regularly. Lot number will be recorded and referenced on all inventory transactions.

2. Continue annual review of fees for cost recovery.

Response: HHS will continue to review the fee schedule annually and make any necessary fee increases.

Summary

This review is intended to support management of this office in evaluating internal controls over financial issues and inventory. Adherence to and follow through with the recommendations should strengthen internal controls.

Dallas County, Texas
Health Human Services
 International Travel Vaccines

Vaccine	FY 2012 Cost per Dose	Ending Inventory 7/31/2012	Adjustment to Beginning Inventory	Beginning Inventory 8/01/2012	Receipts	Usable Doses Returned	Doses Administered	Issues (Doses Transferred Out/Doses Found)	Adjustment for Vaccine Expiration	Ending Calculated Count 8/31/2012	Ending Calculated Value 8/31/2012	% Physical Count 8/31/2012	Total Ending Inventory Value 8/31/2012	Variance Units	Variance Amount
Hepatitis A Adult	\$ 25.37	327	0	327	0	0	79	0	0	248	\$ 6,291.51	246	\$ 6,240.77	(2)	\$ (50.74)
Hepatitis B Adult	\$ 32.73	697	0	697	0	0	41	0	0	656	\$ 21,488.69	658	\$ 21,534.14	2	\$ 65.45
HIB	\$ 23.15	45	0	45	0	0	6	0	0	39	\$ 902.85	39	\$ 902.85	0	\$ -
HPV-Gardasil	\$ 150.36	94	0	94	0	0	4	0	0	90	\$ 13,532.17	89	\$ 13,381.81	(1)	\$ (150.36)
Influenza (Fluzone)	\$ 12.14	0	0	0	7400	0	186	0	0	7,214	\$ 87,542.80	7210	\$ 87,494.26	(4)	\$ (48.54)
IPV	\$ 25.60	409	0	409	0	0	42	0	0	367	\$ 9,393.46	364	\$ 9,316.67	(3)	\$ (76.79)
Japanese Encephalitis	\$ 207.89	36	0	36	80	0	4	0	0	112	\$ 23,283.95	112	\$ 23,283.95	0	\$ -
MMR	\$ 60.70	179	0	179	100	0	61	0	0	218	\$ 13,231.51	217	\$ 13,170.82	(1)	\$ (60.69)
Meningococcal (Menactra)	\$ 74.91	389	0	389	700	0	399	0	0	690	\$ 51,688.11	683	\$ 51,163.74	(7)	\$ (524.37)
Meningococcal (Menomune)	\$ 111.68	21	0	21	80	0	5	0	0	96	\$ 10,720.92	96	\$ 10,720.92	0	\$ -
Pneumococcal (PPSV23)	\$ 63.51	75	0	75	0	0	8	0	0	67	\$ 4,255.17	67	\$ 4,255.17	0	\$ -
Rabies	\$ 194.31	33	0	33	100	0	7	0	0	126	\$ 24,483.28	126	\$ 24,483.28	0	\$ -
Tetanus/Diphtheria	\$ 20.73	309	0	309	150	0	60	0	0	399	\$ 8,271.27	398	\$ 8,250.54	(1)	\$ (20.73)
TDAP (Adacel)	\$ 31.08	123	0	123	100	0	85	0	0	138	\$ 4,289.18	138	\$ 4,289.18	0	\$ -
Twinnix	\$ 52.14	203	0	203	150	0	47	0	0	306	\$ 15,955.34	305	\$ 15,903.20	(1)	\$ (52.14)
Typhoid (Oral)	\$ 34.40	295	0	295	600	0	63	0	0	832	\$ 28,620.80	830	\$ 28,552.00	(2)	\$ (68.80)
Typhoid (Inject)	\$ 49.69	131	0	131	400	0	86	0	0	445	\$ 22,110.14	448	\$ 22,259.20	3	\$ 149.06
Varicella	\$ 89.91	148	0	148	0	0	122	0	0	26	\$ 2,337.66	25	\$ 2,247.75	(1)	\$ (89.91)
Yellow Fever**	\$ 87.58	675	0	675	300	0	99	0	0	876	\$ 76,717.33	875	\$ 76,629.75	(1)	\$ (87.58)
Zostavax	\$ -	0	0	0	0	0	0	0	0	0	\$ -	0	\$ -	0	\$ -
DT Pedi	\$ 33.34	10	0	10	0	0	0	0	0	10	\$ 333.40	10	\$ 333.40	0	\$ -
Dtap -HepB-IPV (Pediarix)	\$ 64.46	50	0	50	0	0	4	0	0	46	\$ 2,965.16	46	\$ 2,965.16	0	\$ -
Dtap-IPV (Kinrix)	\$ 49.42	50	0	50	0	0	11	0	0	39	\$ 1,927.38	39	\$ 1,927.38	0	\$ -
Hep A Ped/Adolescent	\$ 17.96	47	0	47	0	0	20	0	0	27	\$ 484.92	27	\$ 484.92	0	\$ -
Hep B Ped/Adolescent	\$ 12.93	46	0	46	0	0	5	0	0	41	\$ 530.25	41	\$ 530.25	0	\$ -
HPV (Ped)	\$ 136.19	39	0	39	0	0	2	0	0	37	\$ 5,039.03	38	\$ 5,175.22	1	\$ 136.19
PCV-13	\$ 128.76	50	0	50	0	0	10	0	0	40	\$ 5,150.40	41	\$ 5,279.16	1	\$ 128.76
Rota Virus	\$ 74.79	10	0	10	0	0	0	0	0	10	\$ 747.90	10	\$ 747.90	0	\$ -
Totals		4,491	0	4,491	10,160	0	1,456	0	0	13,195	\$ 442,274.58	13,178	\$ 441,523.39	(17)	\$ (751.19)

¥ From FY 2012 Adult Biological Report

¤ From FY 2012 Count Sheet